ArticleNature communications2026
Hemadyne: accordion-inspired perfusion for microphysiological systems.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hemadyne: accordion-inspired perfusion for microphysiological systems.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A crucial factor limiting the physiological relevance, reproducibility and ease of adoption of microphysiological systems is the constrained non-specific design and performance of existing perfusion systems. Inspired by the physics of the accordion music instrument, we have engineered Hemadyne, a standalone mechanical pump with compact footprint that operates without any additional instruments. The pump is paired with a custom-built control algorithm to reproduce clinical waveforms with a 400-millisecond temporal resolution. We show that Hemadyne is able to replicate Doppler ultrasound waveforms of patient hemodynamics with nearly absolute spatiotemporal fidelity. We also demonstrate that Hemadyne surpasses conventional technologies, providing sustainable and stable flow, including transient forward and backward flows, comprising multiple amplitudes and phases within a single period, with high signal-to-noise ratio and fast response times. Next, we show that Hemadyne sustains the long-term culture of primary human endothelial cells in a vessel-chip for up to 60 days. Further, we apply the system to dissect the role of hemodynamic diastolic rest phase as a determinant of endothelial homeostasis, while revealing a differential response to arterial and venous endothelial cells. Finally, we demonstrate that Hemadyne is able to recapitulate the age-associated pathological effect of transient diastolic retrograde flow on arterial endothelial cells, that animal models cannot reproduce. Taken together, our findings indicate that Hemadyne is an enabling technology that improves operational longevity and physiological relevance of microphysiological systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.